GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Tax Provision

Cabio Biotech (Wuhan) Co (SHSE:688089) Tax Provision : ¥-22.7 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Tax Provision?

Cabio Biotech (Wuhan) Co's tax provision for the three months ended in Mar. 2025 was ¥-7.3 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-22.7 Mil.

Cabio Biotech (Wuhan) Co Tax Provision Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Tax Provision Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.80 -20.77 -16.56 -13.63 -19.69

Cabio Biotech (Wuhan) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.39 -7.33 -1.41 -6.57 -7.35

Cabio Biotech (Wuhan) Co Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-22.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabio Biotech (Wuhan) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Tax Provision
Comparable Companies
SHSE:688253 SZSE:301333 SHSE:688767 SHSE:688687 SHSE:603718 BJSE:833575 SHSE:688197 SHSE:688293 SHSE:603566 BJSE:430047 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430075
Website
http://www.cabio.cn
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Shang Yun Core technical personnel
Xiao Min senior management
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines